Conference Coverage

Extent of breast surgery is tied to quality of life among young breast cancer survivors


 

REPORTING FROM SABCS 2018

SAN ANTONIO – Younger breast cancer patients who undergo unilateral or bilateral mastectomy report lower breast satisfaction and poorer psychosocial and sexual well-being than counterparts who undergo breast-conserving surgery, finds a cross-sectional cohort study presented by lead investigator Laura S. Dominici, MD, FACS, at the San Antonio Breast Cancer Symposium.

The 560 women studied had a mean age of 37 years and had completed the BREAST-Q questionnaire a median of 5.8 years after their breast cancer diagnosis. Results showed that the mean score for satisfaction with breasts was 65.5 with breast-conserving surgery, 59.3 with unilateral mastectomy, and 60.4 with bilateral mastectomy (P = .008). The mastectomy groups also had poorer scores for psychosocial well-being (P less than .001) and sexual well-being (P less than .001), but not physical well-being. Most of the differences remained significant in meta-analysis. In a video interview, Dr. Dominici, of Dana-Farber Cancer Institute, Boston, discussed worry and anxiety about recurrence and second cancers as drivers of choosing mastectomy, generalizability of the study’s findings, and strategies for incorporating this new information into counseling and shared decision making.

Dr. Dominici disclosed that she had no conflicts of interest. The study was funded by the Agency for Healthcare Research and Quality, Susan G. Komen, the Breast Cancer Research Foundation, and The Pink Agenda.

Recommended Reading

Adjuvant capecitabine found disappointing in TNBC
MDedge Hematology and Oncology
Low-dose tamoxifen halves recurrence of breast intraepithelial neoplasia
MDedge Hematology and Oncology
Small absolute difference between partial and whole breast irradiation
MDedge Hematology and Oncology
Nothing to gain from chemo after pCR achieved
MDedge Hematology and Oncology
RT of lymph nodes as good as dissection for the long-term
MDedge Hematology and Oncology
CTC matches MD judgment for mBC therapeutic choice
MDedge Hematology and Oncology
TNBC survival appears better when adjuvant chemotherapy is delivered within 30 days
MDedge Hematology and Oncology
Tamoxifen at 5 mg halves recurrence of breast intraepithelial neoplasia
MDedge Hematology and Oncology
Extended anastrozole improves DFS, distant DFS
MDedge Hematology and Oncology
pCR may obviate need for adjuvant chemotherapy
MDedge Hematology and Oncology